BIB stock icon

ProShares Ultra NASDAQ Biotechnology
BIB

$68.41
2.27%

Market Cap: 109M

0
Funds holding %
of 6,702 funds
–
Analysts bullish %
–
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

4.37% less ownership

Funds ownership: 9.04% [Q4 2023] → 4.66% (-4.37%) [Q1 2024]

5% less funds holding

Funds holding: 21 [Q4 2023] → 20 (-1) [Q1 2024]

12% less call options, than puts

Call options by funds: $1.3M | Put options by funds: $1.48M

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

45% less capital invested

Capital invested by funds: $8.14M [Q4 2023] → $4.51M (-$3.64M) [Q1 2024]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for BIB.

See Analyst Rankings

Financial journalist opinion

Positive
InvestorPlace
4 months ago
Wall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Some of the market's favorite biotech stocks have created immense wealth, as in the recent weight-loss drug stock boom.  On May 26, Viking Therapeutics (NASDAQ: VKTX ) was trading around $20.25.
Wall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Positive
InvestorPlace
5 months ago
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
With new innovation, high demand for better treatment, pharmaceutical companies strengthening pipelines and a resurgence of mergers and acquisitions, biotech stocks could offer some of the most explosive opportunities of the year. “What's more, big pharmaceutical companies with sizable piles of cash and the need to address patent expirations on some top-selling products later this decade will be hunting for companies with innovative drugs in development,” says Morningstar.com.
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
Positive
Seeking Alpha
6 months ago
Equity CEFs/ETFs: Top Picks For 2024 - Part II
In Part I of my Top Picks For 2024, I explained why we saw such extreme valuation losses in most equity CEFs in 2023 and what that could-mean for 2024. In my opinion, liquidity was the over-riding factor for why so few stocks, think Magnificent 7, received the lion's share of buy-interest while most everything else suffered, including equity CEFs. But just because the Federal Reserve will continue its Quantitative Tapering doesn't mean that other Fed programs won't increase liquidity in other places.
Equity CEFs/ETFs: Top Picks For 2024 - Part II
See News Rankings